INTRODUCTION {#S1}
============

Patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), have a significantly higher risk of developing colorectal cancer (CRC). Colitis-associated colorectal cancer (CAC) is considered the most serious complication of IBD ([@R20]). Interferon regulatory factor 8 (IRF8) is a transcription factor of the interferon (IFN) regulatory factor family, which plays an essential role in lineage-specific hematopoietic differentiation ([@R9]; [@R13]; [@R18]). IRF8 is also expressed and functional in non-hematopoietic epithelial cells ([@R40]). Genome-wide association studies (GWASs) have implied that IRF8 plays a role in IBD ([@R2]; [@R8]; [@R15]). More recently, IRF8 has been shown to function as a critical regulator of inflammation through regulating cytokine production and pyroptosis ([@R16]). However, the mechanism underlying IRF8 function in CAC is unknown.

Interleukin 10 (IL-10) is historically considered to be an anti-inflammatory cytokine that functions to suppress chronic inflammation and CAC ([@R22]; [@R28]; [@R30]). However, IL-10 also plays a key role in the modulation of host cancer immune surveillance ([@R7]; [@R29]). Overexpression of IL-10 or treatment with a pegylated IL-10 led to tumor rejection and long-lasting tumor immunity in tumor-bearing mice ([@R31]). IL-10 suppresses tumor development through inducing cytotoxic T lymphocyte (CTL) activation ([@R29]) and inhibiting inflammatory cytokine production to hamper Treg and myeloid-derived suppressor cells (MDSCs) ([@R36]). IL-10 is also identified by GWASs as being associated with IBD ([@R15]). Inconsistent with GWAS observations, IL-10 also has been shown to act as a tumor promoter. An IL-10 autocrine or paracrine loop enhances tumor cell survival and escape from host immune surveillance ([@R10]; [@R33]). However, the molecular mechanisms underlying the complex functions of IL-10 as an anti-inflammatory cytokine and an IBD-associated risk factor and the contrasting roles of IL-10 in cancer immune surveillance and tumor evasion have not been identified.

We aimed at determining the mechanistic link between IL-10 and IRF8 in the context of chronic colonic inflammation and to test the hypothesis that IRF8 is a CAC suppressor. To this end, we determined that the MDSC-IL-10-signal transducer and activator of transcription 3 (STAT3)-DNA methyltransferase (DNMT) 3b-IRF8 pathway links chronic inflammation to colon cancer initiation.

RESULTS {#S2}
=======

IRF8 Functions as a Suppressor of Spontaneous Colon Cancer {#S3}
----------------------------------------------------------

Mice with IRF8 deficiency only in colon epithelial cells (termed IRF8cKO) were created by crossing *Irf8*-floxed mice with villincre mice ([Figures S1A and S1B](#SD1){ref-type="supplementary-material"}) with the deletion of exon 2 ([Figure S1C](#SD1){ref-type="supplementary-material"}). As reported in the literature, we observed that IRF8KO mice exhibit elevated levels of CD11b^+^Gr1^+^ MDSCs as compared to wild-type (WT) mice. However, IRF8cKO mice exhibit similar levels of CD11b^+^Gr1^+^ MDSCs to WT mice ([Figures S2A and S2C](#SD1){ref-type="supplementary-material"}). The profiles of CD4^+^ and CD8^+^ T cells in IRF8cKO mice are also similar to those of WT mice ([Figures S2B and S2C](#SD1){ref-type="supplementary-material"}). IRF8cKO mice are more susceptible to chronic inflammation because dextran sodium sulfate (DSS) treatment resulted in significant greater weight loss and higher mortality as compared to C57BL/6, heterogenous *Irf8*-floxed (*Irf8*^*f*+/−^), and heterogenous villin-cre (*Vil1-cre*^+/−^) control mice ([Figure 1A](#F1){ref-type="fig"}). IRF8 deficiency also results in significantly increased numbers of Ki67^+^ colon epithelial cells in the stem cell and amplifying proliferating cell zones of the crypt as compared to WT mice ([Figures 1B and 1C](#F1){ref-type="fig"}). Epithelial cells in the differentiating cell zone of the colon exhibit high levels of spontaneous apoptosis. IRF8 deficiency results in significantly decreased spontaneous apoptosis of these differentiating cells ([Figures 1D and 1E](#F1){ref-type="fig"}). The Ki67 mRNA level is also significantly higher in the colon of IRF8cKO mice as compared to WT mice ([Figure 1F](#F1){ref-type="fig"}). The IRF8 WT control mice and IRF8cKO mice were then treated with three cycles of azoxymethane (AOM)-DSS, and the colon tissues were analyzed for tumor nodules. Significantly more tumor nodules were observed in the colon tissues of IRF8cKO mice as compared to the C57BL/6, *Irf8*^*f*+/−^, and *Vil1-cre*^+/−^ control mice ([Figure 1G](#F1){ref-type="fig"}). Analysis of IRF8 mRNA levels in normal human colon and colorectal carcinoma revealed that IRF8 is downregulated in the tumor tissues as compared to normal tissues ([Figure 1H](#F1){ref-type="fig"}). We therefore conclude that IRF8 is a suppressor of inflammationinduced spontaneous colon cancer.

Chronic Inflammation Silences IRF8 Expression {#S4}
---------------------------------------------

An IRF8-GFP reporter mouse was used to monitor IRF8 expression ([@R38]). IRF8 is expressed in the colon crypt in a gradient pattern, with the highest IRF8 protein levels in the differentiating and differentiated cell zones and relatively low levels in the amplifying proliferating and stem cell zones of tumor-free mice. However, IRF8 expression is silenced in the AOM-DSS-treated mice with colon cancer ([Figure 2A](#F2){ref-type="fig"}). RT-PCR and western blotting analysis validated that IRF8 mRNA and protein levels are higher in colon tissues from tumor-free mice than in tumorbearing colon tissues from AOM-DSS-treated mice ([Figure 2B](#F2){ref-type="fig"}). The IRF8 protein level in normal colon tissue is as high as it is in myeloid cells ([Figure 2C](#F2){ref-type="fig"}). IRF-GFP reporter mice were then treated with DSS only, followed by water recovery. DSS treatment alone is sufficient to diminish IRF8 protein levels in colon epithelial cells, and IRF8 is silenced approximately 21 days after DSS treatment ([Figure 2D](#F2){ref-type="fig"}). RT-PCR and western blotting analysis of the colon tissues validated that *Irf8* expression is silenced 21 days after treatment with DSS ([Figure 2E](#F2){ref-type="fig"}). These observations demonstrate that chronic inflammation silences IRF8 expression in colon epithelial cells.

Chronic Inflammation Induces the *Irf8* Promoter DNA Hypermethylation in Colon Carcinoma Cells {#S5}
----------------------------------------------------------------------------------------------

Because IRF8 is silenced in colon carcinoma cells by DNA methylation ([@R25]), we hypothesized that DSS-induced inflammation silences IRF8 expression in colon epithelial cells. To test this hypothesis, we analyzed DNA methylation in the *Irf8* promoter in normal colon and tumor-bearing colon tissues. The *Irf8* promoter contains a CpG island ([Figure 3A](#F3){ref-type="fig"}). Bisulfite DNA sequencing revealed no methylated CpG in normal colon tissues. However, the majority of CpGs were methylated in the AOM-DSS-induced colon tumor tissues ([Figure 3A](#F3){ref-type="fig"}). Methylation-sensitive PCR validated that the *Irf8* promoter DNA is hypermethylated ([Figure 3B](#F3){ref-type="fig"}). The *Irf8* promoter CpG island is partially methylated in the human colon epithelial CCD841 cells but heavily methylated in human colon carcinoma HCT116 cells ([Figure 3C](#F3){ref-type="fig"}). Analysis of The Cancer Genome Atlas (TCGA) datasets revealed the *Irf8* promoter DNA has significantly higher methylation levels in tumors than in normal colon tissue ([Figure 3D](#F3){ref-type="fig"}). Knocking out DNMT1 alone results in no demethylation of the I*rf8* promoter and a minimal increase in IRF8 expression, whereas knocking out DNMT3b alone results in demethylation of the *Irf8* promoter and upregulation of IRF8 expression in HCT116 cells. However, knocking out both DNMT1 and DNMT3b leads to demethylation of the *Irf8* promoter and upregulation of IRF8 expression in HCT116 cells ([Figures 3E and 3F](#F3){ref-type="fig"}). We therefore conclude that DSS-induced chronic inflammation upregulates DNMT1 and DNMT3b to methylate the *Irf8* promoter.

Chronic Inflammation Induces Upregulation of DNMT1 and DNMT3b in Colon Epithelial Cells {#S6}
---------------------------------------------------------------------------------------

DNMT1 and DNMT3b protein and transcript levels are significantly higher in tumor tissues as compared to normal colon tissues, whereas DNMT3a expression levels are not significantly different between the normal and the tumor-bearing colon tissues ([Figure 4A](#F4){ref-type="fig"}). DNMT1 and DNMT3b expression levels are also significantly higher in human colorectal carcinoma tissues as compared to normal colon tissues ([Figure 4B](#F4){ref-type="fig"}). DSS treatment induces inflammation in the mouse colon, and the degree of inflammation increases with time, with the highest inflammation grade observed 21 days after DSS treatment ([Figure 4C](#F4){ref-type="fig"}). DNMT3a is constitutively expressed in colon tissues, and the expression of DNMT1 and DNMT3b is upregulated approximately 21 days after DSS treatment ([Figure 4D](#F4){ref-type="fig"}). We therefore conclude that DSS-induced chronic inflammation upregulates DNMT1 and DNMT3b in the colon.

MDSCs and IL-10 Are Increased in the Inflamed Colon {#S7}
---------------------------------------------------

DSS treatment increased the expression levels of IL-6, IL-10, IL-22, IFNγ, and CD11b in the colon (Figures [5A](#F5){ref-type="fig"} and [S3](#SD1){ref-type="supplementary-material"}). The upregulation kinetics of IL-10 and CD11b correlate with IRF8 silencing in the colon tissue (Figures [2](#F2){ref-type="fig"} and [5A](#F5){ref-type="fig"}). CD11b and IL-10 are elevated in tumor-bearing tissues as compared to normal colon tissues ([Figure 5B](#F5){ref-type="fig"}), and IL-10 is elevated in CD11b^+^ cells upon DSS-induced inflammation ([Figure S4](#SD1){ref-type="supplementary-material"}). Consistent with increased CD11b expression, analysis of spleen cells from DSS-treated mice validated that CD11b^+^Gr1^+^ MDSCs are significantly increased after DSS treatment ([Figures 5C and 5D](#F5){ref-type="fig"}). CD4^+^ and CD8^+^ T cell frequencies only decreased 21 days after DSS treatment but recovered at day 28 ([Figure S5](#SD1){ref-type="supplementary-material"}). Cells were then extracted from the lamina propria of colon tissues and analyzed for MDSC frequencies. It is clear that DSS treatment also significantly increased MDSC frequencies in the lamina propria ([Figure 5E](#F5){ref-type="fig"}). DSS treatment significantly increased the frequencies of IL-10^+^ cells in the spleen ([Figures 5F and 5G](#F5){ref-type="fig"}) and the lamina propria ([Figures 5H and 5I](#F5){ref-type="fig"}). Furthermore, the majority of IL-10^+^ cells in both spleen and the lamina propria are also CD11b^+^Gr1^+^ ([Figures 5F--5I](#F5){ref-type="fig"}). We therefore conclude that DSS-induced inflammation increases CD11b^+^Gr1^+^ MDSCs that produce IL-10.

IL-10 Upregulates DNMT1 and DNMT3b Expression in Colon Epithelial Cells {#S8}
-----------------------------------------------------------------------

To determine whether IL-10 regulates DNMT1 and DNMT3b expression, we treated CCD841 and HT29 cells with recombinant IL-10 protein. RT-PCR analysis revealed that IL-10 stimulated DNMT1 and DNMT3b expression in a dose-dependent manner ([Figure 6A](#F6){ref-type="fig"}). Western blot analyses show that DNMT1 and DNMT3b protein levels are increased and the IRF8 protein level is decreased in IL-10-treated cells ([Figure 6B](#F6){ref-type="fig"}). To validate the above findings that IL-10 regulates DNMT1 and DNMT3b expression in colon epithelial cells, we treated WT and IL-10 KO mice with DSS and analyzed colon tissues for DNMT1 and DNMT3b protein levels. Western blot analyses indicate high DNMT1 protein levels in the colon tissues from DSS-treated mice. However, DSS failed to induce DNMT3b in the colon tissues of IL-10 KO mice ([Figure 6C](#F6){ref-type="fig"}). Furthermore, colon tissues from IL-10 KO mice exhibited significantly higher IRF8 expression levels after DSS treatment ([Figure 6D](#F6){ref-type="fig"}). Luciferase reporter assay with methylated IRF8 promoter indicated that methylation silences *Irf8* promoter activity ([Figure 6E](#F6){ref-type="fig"}). These observations indicate that IL-10 upregulates DNMT3b expression in colon epithelial cells to silence IRF8 expression *in vivo*.

IL-10 Upregulates DNMT1 and DNMT3b Expression through the Activation of STAT3 {#S9}
-----------------------------------------------------------------------------

DSS treatment induced the activation of both STAT1 and STAT3 ([Figure 7A](#F7){ref-type="fig"}). STAT3 activation kinetics correlate with DNMT1 and DNMT3b upregulation (Figures [4D](#F4){ref-type="fig"} and [7A](#F7){ref-type="fig"}). IL-10 has been implicated in the induction of STAT3 activation in fibroblasts ([@R1]). We therefore sought to test the hypothesis that IL-10 activates STAT3 to upregulate the expression of DNMT1 and DNMT3b in colon epithelial cells. We observed that IL-10 treatment induced STAT3 activation in both normal colon epithelial cells and colon carcinoma cells ([Figure 7B](#F7){ref-type="fig"}). IFNγ treatment activated STAT1 and increased IRF8 expression in HT29 and CCD841 cells *in vitro* ([Figure S6A](#SD1){ref-type="supplementary-material"}). IL-6 and IL-22 treatments did not induce STAT1 activation ([Figure S6A](#SD1){ref-type="supplementary-material"}), but they did induce STAT3 activation, the upregulation of DNMT1 and DNMT3b, and the downregulation of IRF8 ([Figures S6A and S6B](#SD1){ref-type="supplementary-material"}).

To determine whether the activated STAT3 directly regulates DNMT1 and DNMT3b expression, CCD841 and HT29 cells were treated with IL-10 and analyzed for phospho-STAT3 (pSTAT3) protein binding to the *Dnmt1* and *Dnmt3b* promoter chromatin. Chromatin immunoprecipitation (ChIP) analysis revealed that pSTAT3 binds to the *Dnmt1* promoter region downstream of the *Dnmt1* transcription initiation site ([Figure 7C](#F7){ref-type="fig"}), whereas pSTAT3 binds to the *Dnmt3b* promoter region upstream of the *Dnmt3b* transcription initiation site ([Figure 7D](#F7){ref-type="fig"}). The *DNMT1* (P2 fragment, [Figure 7E](#F7){ref-type="fig"}) and *DNMT3b* (P4 fragment, [Figure 7F](#F7){ref-type="fig"}) promoter DNA regions that contain the pSTAT3-binding sites were cloned to the luciferase reporter, respectively. The adjacent DNA fragments (P1 fragment, [Figure 7E](#F7){ref-type="fig"}, and P3 fragment, [Figure 7F](#F7){ref-type="fig"}) were also cloned to the luciferase reporter plasmid. While insertion of the pSTAT3-binding site DNA fragments did not increase *DNMT1* or *DNMT3b* promoter activity in CCD841 and HT29 cells, IL-10 treatment induces significantly higher reporter activity in both CCD841 and HT29 cells transfected with the pSTAT3-binding site DNA fragments as compared to cells transfected with the negative control DNA fragments ([Figures 7E and 7F](#F7){ref-type="fig"}). Our data determine that IL-10 activates STAT3 to upregulate DNMT1 and DNMT3b expression in colon epithelial cells.

DISCUSSION {#S10}
==========

A molecular connection between proinflammatory pathways and CAC came from a study using a colitis mouse model with deficiency in nuclear factor κB (NF-κB) activation, and it was determined that NF-κB acts as an oncogene for CAC ([@R11]). IBD susceptibility genes such as NOD2 may suppress CAC through the inhibition of NF-κB activation ([@R37]). Here, we determined that the newly identified UC susceptibility gene IRF8 functions as a CAC suppressor, and chronic inflammation promotes CAC through silencing IRF8 expression by an epigenomic mechanism.

IRF8 expression is regulated by promoter methylation in a tissue-dependent manner. In osteoclast progenitors, thymidine phosphorylase activated the phosphoinositide 3-kinase (PI3K)/ Akt signaling pathway to increase the expression of DNMT3a, but not DNMT1 and DNMT3b, to hypermethylate the *Irf8* promoter ([@R24]). Consistent with the roles for DNMT1 and DNMT3b in genome-wide DNA methylation in human colon carcinoma cells ([@R32]), we observed that the expression levels of DNMT1 and DNMT3b, but not DNMT3a, are upregulated in CAC as compared to normal colon tissues. Furthermore, DSS-induced chronic inflammation is sufficient to upregulate DNMT1 and DNMT3b and the *Irf8* promoter methylation in colonic epithelial cells. Aberrant DNA methylation of CpG islands has been widely observed in human colorectal carcinoma and is significantly associated with gene silencing through gene-specific mechanisms ([@R19]; [@R39]). CpG island methylator phenotype-positive colorectal tumors represent a distinct subset of colorectal tumors, including almost all cases of tumors with the BRAF mutation. Methylation of MLH1 often links to sporadic cases of colorectal tumor mismatch repair deficiency ([@R39]). Therefore, DNA methylation is a key mechanism that colorectal tumors use to promote the disease. Our data point to a previously uncharacterized mechanism underlying the chronic colonic inflammation promotion of CAC: chronic inflammation induces the upregulation of DNMT1 and DNMT3b to hypermethylate the *irf8* promoter CpG island and silence the tumor suppressor gene *Irf8* in colonic epithelial cells.

Although IL-10 acts as an anti-inflammatory cytokine to suppress inflammation and CAC ([@R22]; [@R28]; [@R30]), GWAS has identified *Il10* as a susceptibility locus associated with IBD ([@R15]).It is generally believed that IL-10 suppresses inflammation-mediated colorectal cancer by inhibiting the production of proinflammatory cytokines, including IFNγ, tumor necrosis factor α (TNF-α), IL-1β, IL-6, and IL-12 ([@R27]). Many of the proinflammatory cytokines are abundantly expressed in chronic inflammatory lesions and the tumor tissues, but it was reported that, unlike these proinflammatory cytokines, IL-10 is not expressed in tumor tissues ([@R29]). It is well known that IL-10 is expressed in B and T cells ([@R4]; [@R26]; [@R41]). IL-10 is also expressed in myeloid cells such as MDSCs ([@R12]; [@R34]) to promote tumor growth. MDSCs are induced by inflammatory factors that crosstalk with tumor cells in the tumor microenvironment to promote tumor growth through immunological and non-immunological mechanisms ([@R3]; [@R5], [@R6]; [@R17]). In this study, we observed that IL-10 is abundantly expressed in MDSCs in colon tissues and second lymphoid organs under conditions of chronic inflammation. We further demonstrated that IL-10 activates STAT3, which directly binds to the *Dnmt1* and *Dnmt3b* promoter regions to regulate DNMT1 and DNMT3b expression in colonic epithelial and colon carcinoma cells. The molecular link between IL-10 and DNMT3b is further validated by our observation in inflamed colon tissues that the deletion of IL-10 results in the loss of DNMT3b expression. Since it is known that IL-10 inhibits the IL-6-mediated STAT3 activation in MDSCs ([@R21]), it is possible that IL-10 KO colon tissues express a high level of DNMT1 because IL-10 deficiency likely leads to increased IL-6 and resultant DNMT1 upregulation under conditions of chronic inflammation ([@R23]). Therefore, in contrast to IL-10 functioning as a suppressor of CAC, our data indicate that IL-10 plays a promoting role in chronic inflammation-mediated CAC. These contrasting roles of IL-10 in CAC may be due to the timing and sequence of IL-10 activation and function. IL-10 is an inhibitor of NF-κB ([@R35]), and NF-κB is essential for CAC ([@R11]). Therefore, it is expected that chronic inflammation induces a higher and earlier incidence of colon tumors in *Il0*KO mice since loss of IL-10 function occurs before the start of inflammation. However, in the AOM-DSS WT mouse model, IL-10-producing MDSCs accumulate only at a late stage of inflammation, and therefore IL-10 inhibition of NF-κB activation may not be relevant for the initiation of NF-κB-dependent epithelial cell transformation. Instead, higher levels of IL-10 in the colon lamina propria activate the STAT3 pathway to promote tumor growth through DNMT3b-mediated IRF8 silencing. Evaluations of these contrasting roles of IL-10 in CAC require further study. Nevertheless, our data demonstrate that the MDSC-IL-10-STAT3-DNMT3b-IRF8 circuit represents another pathway linking chronic inflammation and CAC.

STAR★METHODS {#S11}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S12}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kebin Liu (<Kliu@augusta.edu>)

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Mice {#S14}

C57BL/6J, *loxp*-flanked *Irf8* \[B6(Cg)-*Irf8*^tm1.1Hm^/J\], villin-cre \[B6.Cg-Tg(*Vil1-cre*)1000Gum/J\], *Il10KO* mice \[B6.129P2-*Il10*^*tm1Cgn*^/J\], and IRF8-GFP reporter mice \[B6(Cg)-*Irf8*^*tm2.1Hm*^/J\] were obtained from the Jackson Laboratory (Bar Harbor, ME). Mice with a conditional IRF8 knock out were created by crossing the *loxp*-flanked *Irf8* mouse with the villin-cre mouse. IRF8KO mice were kindly provided by Dr. Keiko Ozato (National Institutes of Health, Bethesda, MD). All mice used in this study were aged between 2--3 months old at the start of the experiment, fed ad *libitum*, and maintained on a 12-hour light/dark cycle at the animal facility of Augusta University. All animal studies are approved in advance by Augusta University Institutional Animal Care and Use Committee (Protocol\# 2008--0162).

### Cell lines {#S15}

The human colon epithelial cell line CCD841 and human colon carcinoma HT29 and HCT116 cell lines were obtained from American Type Culture (Manassas, VA). HCT116DNMT1^−/−^, HCT116DNMT3b^−/−^, and HCT116DNMT1^−/−^ DNMT3b^−/−^ (DKO) were kindly provided by Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD). CCD841 and HT29 Cells were treated with recombinant IL10, IL6 or IL22 (Biolegend, San Deigo, CA), or recombinant IFNγ (R&D, Minneapolis, MN) for 2 or 24 h and analyzed by western blotting or/and RT-PCR.

METHOD DETAILS {#S16}
--------------

### AOM injection and DSS administration (colitis associated cancer mouse model) {#S17}

Mice were injected with azoxymethane (AOM, Sigma-Aldrich, 10 mg/kg body weight) intraperitoneally once, followed by administration of 2% dextran sulfate sodium (DSS, MP Biomedicals, Santa Ana, CA) through the drinking water one day later for one week. DSS was replaced with water for two weeks. The DSS/water cycle was repeated two more times. Mice were maintained with regular drinking water for one more week after the 3^rd^ cycle and then sacrificed for analysis. Colon tissues were dissected from the mice, flushed and cleaned with PBS, cut open longitudinally to examine tumor nodules. Both male and female mice were used in all AOM-DSS model experiments. DSS-model experiments were conducted on male mice.

### Mouse body weight and mortality analysis {#S18}

Mice were weight at the start day of the above AOM-DSS treatment procedure and weighed every two days. The survival percentage of mice throughout the AOM/DSS treatment procedures was assessed from day 0 (AOM injected) to days 70 (day of scarification). For DSS-induced colitis mouse model, Mice were administered 2% dextran sulfate sodium through the drinking water for one week, followed by two weeks with regular water then one more week of 2% DSS drinking water.

### GFP fluorescence visualization {#S19}

Colon tissues were dissected from sacrificed mice, flushed and cleaned with PBS, and cut open longitudinally. The tissues were then fixed in 4% paraformaldehyde (ACROS organic, Waltham, MA) for 24 hr, washed with PBS, incubated in 20% sucrose in PBS for another 24 hr. Tissues were then flash-frozen in optimal cutting temperature compound (OCT-Sakura, Torrance, CA) in dried ice-chilled 100% ethanol. The frozen tissue blocks were stored in --80°C until use. Six mm-thick frozen sections were cut with a cryostat and allowed to dry overnight at room temperature. Sections were then washed with PBS, rinse briefly with water, and then mounted with VECTASHIELD mounting medium containing anti-fading agents with DAPI (Vector laboratories, Burlingame, CA). The tissues were examined under a LSM780 Meta confocal laser microscope (Carl Zeiss, Germany). The captured images were viewed and analyzed using Zeiss Zen Meta imaging 2012 software. Scale bar was calculated with ZEN software then extrapolated to all images with the same magnification power.

### DNA methylation analysis {#S20}

Genomic DNA was extracted from colon tissues, colon tumor and colon carcinoma cell lines using Quick-DNA Miniprep Plus Kit (Zymo Research, Irvine, CA). Sodium bisulfite modification of the genomic DNA was carried out using CpGenome Universal DNA Modification Kit (Millipore, Burlington, MA) according to manufacture instructions. The bisulfite modified genomic DNA was used as a template for PCR amplification of *IRF8* promoter region using Platinum II Taq Hot-Start DNA Polymerase (Invitrogen, Carlsbad, CA) with bisulfite PCR primer pairs designed by MethPrimer program. The PCR amplicon was then cloned to pCR2.1 vector using TA cloning kit (Invitrogen, San Deigo, CA), transformed into One Shot TOP10 Chemically Competent *E. coli* cells (Invitrogen, Carlsbad, CA). Single colonies were grown in 5 mL LB medium and plasmid DNA was purified with Zyppy Plasmid Miniprep Kit (Zymo Research, Irvine, CA). Purified plasmid DNA from individual clones were then sent to Genewiz (South Plainfield, NJ) for sequencing. The methylation status of cytosine was analyzed using Quma program. Methyl-specific (MS-PCR) was carried out on the bisulfite modified genomic DNA using MS-PCR primers designed by MethPrimer program for methylated and unmethylated *irf8* promoter. All primer sequences are listed in [Table S1](#SD1){ref-type="supplementary-material"}.

### Flow cytometry {#S21}

Single cells were prepared from spleens and stained with the following fluorescent dye-conjugated antibodies: FITC-CD11b, PE-Gr1, PE-CD4 and FITC-CD8 (Biolegend, San Deigo, CA). The stained cells were analyzed in a LSR Fortessa (BD Biosciences, San Jose, CA).

### Lamina propria cells extraction and Intracellular staining {#S22}

Colon tissue were dissected from mice, flushed and cleaned with PBS, cut open longitudinally, cut into small pieces and agitated in 1 mM EDTA at 37°C for 30 min. Epithelial cells were filtered away through a 100 μM cell strainer. Colon fragments were then washed with PBS, minced and digested in collagenase/hyaluronidase/DNase mixture at 37°C for 45 min with agitation. The digests were then homogenized, filtered through 100 μm cell strainer. The flow through was then centrifuged at \> 300 g for 10 min and the cells were resuspended in PBS. Cells were first stained with FITC-CD11b- and PE-Gr1-specific antibodies, then fixed and permeabilized with Fixation/Permeabilization Solution Kit (BD Biosciences, San Jose, CA), followed by staining with APC-anti-mouse IL10 antibody (Biolegend, San Deigo, CA). The stained cells were analyzed in a FACS Calibur (BD Biosciences, San Jose, CA) or LSR Fortessa (BD Biosciences, San Jose, CA).

### RT-PCR analysis {#S23}

Total RNA was isolated from cells or tissue using Trizol (Invitrogen, San Diego, CA) according to the manufacturer's instructions, and used for the first strand cDNA synthesis using the MMLV reverse transcriptase (Promega, Madison, WI). The cDNA was then used as template for semiquantitative or real-time PCR analysis with Power SYBR Green PCR Master Mix (ThermoFisher, Waltham, MA) using the StepOne Plus Real Time PCR System (Applied Biosystems, Foster City, CA). The sequences of primers are listed in [Table S1](#SD1){ref-type="supplementary-material"}.

### Western blot analysis {#S24}

Colon tissues and tumors were collected and homogenized into single cell suspension in PBS using an electric homogenizer. Subsequently, cells were lysed in total cell lysis buffer (20 mM HEPES, pH 7.4, 20mM NaCl, 10% glycerol, 1% Triton X-100). Lysates were subjected to standard SDS-polyacrylamide gel electrophoresis (10μg protein/lane) and western blotting procedures using the following primary antibodies: Anti-IRF8 (Cell Signaling, Danvers, MA), Anti-STAT3, anti-pSTAT3, anti-STAT1 and anti-pSTAT1 (BD Biosciences, San Diego, CA), Anti-DNMT1 and Anti-DNMT3b (Abcam, Cambridge, MA). Anti-β-actin (Sigma-Aldrich, St Louis, MO). Anti-Rabbit-HRP (1:5000), Anti-Mouse-HRP (1:5000) secondary antibodies (Cell Signaling, Danvers, MA). Signal was detected using the enhanced chemiluminescence system (ECL; Perkin Elmer, Waltham, MA) and the Xray Film Processor Konica SRX-101A (Konica Minolta, Tokyo, Japan).

### Chromatin Immunoprecipitation (ChIP) {#S25}

ChIP was performed using anti-pSTAT3 (Cell Signaling, Danvers, MA) and the Chromatin Immunoprecipitation (ChIP) Assay Kit (Millipore, Burlington, MA) according to the manufacturer's instructions. Normal rabbit IgG-AC (Santa Cruz Biotechnology, Dallas, TX) was used as negative control for the antibody. The immunoprecipitated genomic DNA was amplified by qPCR using 3 pairs of PCR primers ([Table S1](#SD1){ref-type="supplementary-material"}) covering the region of the *DNMT1* and *DNMT3b* promoter regions.

### Luciferase Reporter Assay {#S26}

Luciferase reporter assay was performed to assess the transcriptional activation of DNMT1 and DNMT3b via the STAT3 bound DNA elements in two different regions of their promoters. For the *DNMT1* P1 promoter region (−2535 to −1629), the *DNMT1* promoter region was amplified from genomic DNA isolated from CCD841 cell line with primers designed from ENSEMBLE GenBank sequence: forward: GTACTCGAGTCCAGGCACACACTACCATTC and reverse: CATAAGCTTCGGGTTCAAGCGATTCTTCTG. Extra nucleotides were added to both ends to generate Xho1 and HindIII unique restriction sites, respectively. The resultant 987-bp PCR product was gel purified and cloned into the pGL3-basic luciferase reporter construct (Promega, Madison, WI) to generate the *DNMT1*-promoter P1-pGL3 construct. For *DNMT3b* P3 promoter region (−3289 to −2364), the *DNMT3b* promoter region was amplified from genomic DNA isolated from CCD841 cell line with primers designed from ENSEMBLE GenBank sequence. Forward: ACTCGG TACCTGTAAAGAAAGGCTGGACGGC and reverse: CATAAGCTTAAATAAACAGGTCTATGGGGAGGG. Extra nucleotides were added to both ends to generate KpnI and HindIII unique restriction sites, respectively. The resultant 926-bp PCR product was gel purified and cloned into the pGL3-basic luciferase reporter construct (Promega, Madison, WI) to generate the *DNMT3b*-promoter P3-pGL3 construct. DNMT1 P2 (−1304 to +179) Promoter-PGL3 construct and DNMT3b P4 (−1263 to +210) promoter-PGL3 construct were obtained from Genecopoeia (Rockville, MD). CCD841 and HT29 were transiently transfected with each of these plasmids or basic PGL3 vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to manufacturer's directions. Twenty-four hr after transfection, the cells were untreated or treated with recombinant human IL10 (Biolegend, San Deigo, CA) at 100 ng/mL for 4 hr. Cells were then washed and lysed. The cell lysates were incubated with luciferon (Promega, Madison, WI) and analyzed for luciferase activity in a Cytation5 imaging reader (Biotek, Winooski, VT). The *IRF8* Promoter PGL3 construct was kindly provided by Dr. Scott Abrams (Roswell Park Comprehensive Cancer Center, Buffalo, NY). To methylate the DNA, the *IRF8* promoter-PGL3 was incubated with M.SssI (New England Biolabs, Ipswich, MA) at 37°C for 1 h. The reaction was stopped by incubation at 65°C for 20 min. The DNA was purified using the PCR purification kit (QIAGEN, Helden, Germany) according to manufacturer's directions. CCD841 and HT29 were transiently transfected with methylated or unmethylated *IRF8* Promoter-PGL3 plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to manufacturer's directions. 24 hr after transfection, cells were lysed and incubated with luciferon (Promega, Madison, WI), analyzed for luciferase activity in a Cytation5 imaging reader (Biotek, Winooski, VT).

### Immunohistochemistry {#S27}

Colon tissues were prepared as SWISS rolls and fixed in 10% formalin overnight. The fixed tissues were processed into paraffin blocks and cut into sections. Sections were dewaxed with Xylene and hydrated in 100%, 90%, 70% and 50% ethanol sequentially. Antigen retrieval was performed using Antigen Unmasking Solution (Vector Lab, Burlingame, CA). Slides were then incubated in 0.3% hydrogen peroxidase for 20 min at room temperature, washed in water, blocked with 2.5% Normal Horse Serum (Vector Lab, Burlingame, CA) for 1 hr, then probed with Anti-Ki67 antibody (Novus, Littleton, CO) overnight at 4°C. Slides were washed three times with PBS-Tween and incubated with HRP Universal Anti-Mouse IgG/Anti-Rabbit IgG Antibody (Vector Lab, Burlingame, CA) for 1 hr. Sections were exposed to ImmPACT DAB Peroxidase Substrate (Vector Lab, Burlingame, CA) for 5 min, washed and counterstained with Harris Hematoxylin (Sigma Aldrich, St. Louis, MO), and incubated for 1 min with 0.1% Sodium Bicarbonate as a bluing reagent. Slides were mounted in VectaMount Permanent Mounting Medium (Vector Lab, Burlingame, CA) and examined under microscope. Ki67^+^ cells at the bottom of crypts were counted. *In situ* TUNEL staining was performed using ApopTag® Plus Peroxidase *In Situ* Apoptosis Kit (Millipore, Burlington, MA) according to the manufacturer's instructions. For each quantification, at least 20 crypts per mouse and at least 3 experimental mice per condition were analyzed. For inflammation score of H&E stained slides, each grade represent the following: Grade 0: Normal colonic mucosa, Grade 1: Loss of one-third of the crypts, Grade 2: Loss of two-thirds of the crypts, Grade 3: The lamina propria is covered with a single layer of epithelium and mild inflammatory cell infiltration is present, Grade 4: Erosions and marked inflammatory cell infiltration are present. Scale bar has been calculated with LAS V4.1 software then extrapolated to all images with the same magnification power.

### TCGA database analysis {#S28}

Human datasets of DNMT1, DNMT3b and IRF8 expression in human primary tumor and normal solid tissue was extracted from TCGA Colon and Rectal Cancer (COADREAD) ploy A^+^ IlluminaHiSeq pancan normalized RNA seq dataset using UCSC Xena Cancer Genomics Browser. Human clinical datasets of the *IRF8* promoter methylation level in human primary tumor and normal solid tissue was extracted from TCGA Colon Cancer (COAD) dataset using MethHC database of DNA Methylation and gene expression in Human Cancer Browser.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S29}
---------------------------------------

Statistical and graphical analyses was performed using Graphpad Prism and Microsoft Excel 2016. Statistical comparisons between any two groups were conducted using unpaired two-tailed Student's t test and *p* values were indicated in their corresponding graphs. p \< 0.05 were considered as statistically significant, and Error bars are indicated as mean ± SD. The immunofluorescence and immunohistochemistry analysis were conducted on mouse tissues for at least 3 sections of at least 3 mice per experimental condition. For each quantification, at least 20 crypts per mouse, and at least 3 experimental mice per condition were analyzed. All flow cytometry data were obtained from at least 3 mice per experimental condition.
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![IRF8 Is a Tumor Suppressor of Chronic Inflammation-Induced Colon Cancer\
(A) WT C57BL/6 (n = 6), heterogenous villin-cre (*Vil-cre*^+/−^) (n = 8), heterogenous *Irf8*-floxed (*Irf8f*^+/−^) (n = 10), and IRF8cKO (n = 13) mice were injected with AOM and then treated with 2% DSS-water cycles, as described in the [Method Details](#S17){ref-type="sec"}. Mice were weighed every 2 days for 28 days. For survival analysis, WT C57BL/6 (n = 16), *Vil-cre*^+/−^ (n = 8), *Irf8f*^+/−^ (n = 10), and IRF8cKO (n = 33) mice were injected with AOM and then treated with the 2% DSS-water cycles. Mice survival was recorded and plotted against days.\
(B and C) Colon tissue from 3-month-old male WT (n = 3) and IRF8cKO (n = 3) mice without any treatment were sectioned and stained with the Ki67-specific antibody. Shown are representative images of one of the three mice (B). Scale bar, 50 μm. (B) Ki67^+^ cells were quantified in 20 crypts per mouse and presented in (C).\
(D and E) Colon tissue from 3-month-old male WT (n = 3) and IRF8cKO (n = 3) mice without any treatment were sectioned and stained by TUNEL. Shown are representative images of one of the three mice (D). Scale bar, 50 μm. TUNEL^+^ cells were quantified in 20 crypts per mouse and presented in (E).\
(F) Colon tissues were collected from WT (n = 5) and IRF8cKO (n = 5) mice and analyzed by qPCR using mouse Ki67 cDNA-specific primers. β-Actin was used as an internal control. Each column represents the mean of triplicates of one mouse. Five mice were used in each group.\
(G) WT C57BL/6 (n = 20), *Vil1-cre*^+/−^ (n = 8), *Irf8*^*f*+/−^ (n = 10), and IRF8cKO (n = 13) mice were treated with the AOM/DSS-water cycles, as described in the [Method Details](#S17){ref-type="sec"}. Shown are representative images of tumor-bearing colon tissues from WT and IRF8cKO mice (left). The tumor nodule numbers were quantified (right).\
(H) IRF8 mRNA expression datasets of human colon carcinoma (n = 380) and normal colon tissues (n = 51) were extracted from TCGA database and compared.](nihms-1517191-f0002){#F1}

![Chronic Inflammation Silences IRF8 Expression in Colonic Epithelial Cells\
(A) IRF8-GFP reporter mice were treated with the AOM-DSS cycle to induce colitis-associated colon cancer. Colon tissues from normal (negative control, n = 3), untreated IRF8-GFP reporter (normal colon, n = 3), and AOM-DSS-treated GFP-reporter (colon cancer, n = 3) mice were fixed and frozen. The frozen sections were stained with DAPI and analyzed for GFP fluorescence intensity using a confocal microscope. Shown are representative images. Scale bar, 50 μm.\
(B) RNA was extracted from the colon tissues of tumor-free (colon, n = 4) and tumor-bearing (tumor, n = 4) mice and cultured RAW264 cells and analyzed for IRF8 mRNA expression levels by qPCR using IRF8-specific primers. β-Actin was used as an internal control. Each column represents the mean of triplicates from one mouse. Four mice were included in each group. Bar, SD. RAW264 was used as a positive control for IRF8 expression.\
(C) Colon tissues of tumor-free (colon, n = 3) and tumor-bearing (tumor, n = 3) mice and cultured RAW264 cells were lysed and analyzed by western blotting analysis using IRF8-specific antibody. β-Actin was used as a normalization control.\
(D) IRF8-GFP reporter mice were treated with DSS in drinking water for 7 days, followed by drinking water for 14 days, then DSS again for 7 days. Colon tissues were collected at days 0, 7, 14, 21, and 28 and analyzed for GFP fluorescence intensity. Normal mice were used as negative controls. Scale bar, 50 μm.\
(E) Total protein lysate was prepared from the colon tissue of mice as in (C) at days 0, 7, 14, 21, and 28 and analyzed for IRF8 protein level by western blotting. β-Actin was used as a normalization control.](nihms-1517191-f0003){#F2}

![The *Irf8* Promoter Is Hypermethylated in Chronic Inflammation-Induced Colon Tumor\
(A) The mouse *Irf8* promoter structure. The CpG islands are indicated by blue, transcription initiation site is indicated by +1. The numbers above the bar indicate the nucleotide location relative to the *Irf8* transcription initiation site. Bottom: genomic DNA was extracted from the colon tissues of normal tumor-free mice (n = 3) and the colon tumor tissues of AOM-DSS-treated mice (n = 3) and modified with bisulfite. The modified genomic DNA was then amplified with bisulfite-modified DNA-specific primers to amplify a CpG island region, as indicated under the CpG island (--348 to +156). The amplified DNA fragments were cloned and sequenced. Each circle represents a CpG dinucleotide. Open circles indicate unmethylated CpG, and closed circles represent methylated CpG.\
(B) The bisulfite-modified genomic DNA as in (A) was also analyzed by methylation-specific (MS)-PCR. U, unmethylated; M, methylated.\
(C) Bisulfite-sequencing analysis of the CpG island region in the *Irf8* promoter of colon epithelial CCD841 and colon carcinoma HCT116 cells. Each circle represents a CpG dinucleotide. Open circles indicate unmethylated CpG, and closed circles represent methylated CpG.\
(D) The *Irf8* promoter DNA methylation datasets of normal human colon tissues and colorectal carcinoma tissues were extracted from TCGA database and compared.\
(E) MS-PCR analysis of the *Irf8* promoter region in WT, DNMT1^−/−^, DNMT3b^−/−^ and DKO of HCT116 cells. U, unmethylated; M, methylated.\
(F) RNA was extracted from WT, DNMT1^−/−^, DNMT3b^−/−^, and DKO of HCT116 cells and analyzed for IRF8 mRNA expression levels by semiquantitative RT-PCR (right top) and qPCR (left) using β-actin as an internal control. Bar, SD. Bottom right: the IRF8 protein level was analyzed by western blotting using IRF8-specific antibody. β-Actin was used as a normalization control.](nihms-1517191-f0004){#F3}

![Chronic Inflammation Upregulates DNMT1 and DNMT3b Expression in Colonic Epithelial Cells\
(A) RNA was isolated from colon tissues of tumor-free control mice (n = 3) and tumor tissues of AOM-DSS-treated mice (n = 3) and analyzed for the expression levels of DNMT1, DNMT3a, and DNMT3b by semiquantitative RT-PCR (left) and qPCR (right) using β-actin as an internal control. Each column represents the mean of triplicates from one mouse. Bar, SD. Three mice are included in each group.\
(B) DNMT1 and DNMT3b mRNA expression datasets in normal human colon tissues (n = 51) and human colorectal carcinoma tissues (n = 380) were extracted from TCGA database and compared.\
(C) WT C57BL/6 mice were treated with the 2% DSS-water cycle, as described in the [STAR Methods](#S11){ref-type="sec"}. Colon tissues were collected at the indicated time points (n = 3) and sectioned and stained by H&E. The stained sections were analyzed for the inflammation scores based on the grades, as described in [STAR Methods](#S11){ref-type="sec"}. Scale bar, 100 μm.\
(D) RNA was extracted from the colon tissues of mice treated with the 2% DSS-water cycle, as described in [STAR Methods](#S11){ref-type="sec"} at the indicated time points, and analyzed for *Dnmt1*, *Dnmt3a*, and *Dnmt3b* mRNA levels by RT-PCR.](nihms-1517191-f0005){#F4}

![Chronic Inflammation Induces IL-10+ MDSC Accumulation in Colon Lamina Propria\
(A) RNA was isolated from colon tissues from mice treated with DSS at days 0, 7,14,21, and 28 and analyzed for IL-10 and CD11b mRNA expression levels by RT-PCR.\
(B) RNA was isolated from colon tissues from tumor-free control mice (n = 3) and from tumor tissues of AOM/DSS-treated mice (n = 3) and analyzed for the expression levels of IL-10 and CD11b by semiquantitative RT-PCR (left) and q-RT-PCR (right) using β-actin as an internal control. Each column represents the mean of triplicates of one mouse. Bar, SD.\
(C) CD11b^+^Gr1^+^ MDSC profiles in the spleen cells of mice at days 0, 7, 14, 21, and 28 after DSS treatment, as in (A). Shown are representative results from one of three mice.\
(D) Quantitation of CD11b^+^Gr1^+^, as shown in (C). Bar, SD.\
(E) CD11b^+^Gr1^+^ MDSC levels in the lamina propria of colon tissues from control mice (n = 3) and DSS-treated mice (n = 3). Shown are representative results. The percentage of CD11b^+^ Gr1^+^ cells was quantified (right). Bar, SD.\
(F) Spleen cells were stained with CD11b- and Gr1-specific antibodies, followed by intracellular staining with IL-10-specific antibody. The IL-10^+^ cells were then gated and analyzed for CD11b^+^Gr1^+^ cells. Shown are representative results from one of three mice.\
(G) Quantification of the percentage of IL10^+^ spleen cells (left) and the percentage of CD11b^+^Gr1^+^ in the IL-10^+^ spleen cells (right). Bar, SD.\
(H) Lamina propria cells were extracted from colon tissues and stained with CD11b- and Gr1-specific antibodies, followed by intracellular staining with IL-10-specific antibody. The IL-10^+^ cells were then gated and analyzed for CD11b^+^Gr1^+^ cells. Shown are representative results from one of three mice.\
(I) Quantification of the percentage of IL-10^+^ lamina propria cells (left) and the percentage of CD11b^+^Gr1^+^ in the IL-10^+^ lamina propria cells (right). Bar, SD.](nihms-1517191-f0006){#F5}

![IL-10 Upregulates DNMT1 and DNMT3b Expression in Colon Epithelial and Carcinoma Cells\
(A) Colonic epithelial CCD841 and colon carcinoma HT29 cells were treated with recombinant IL-10 at the indicated doses for 24 hr and analyzed for *DNMT1* and *DNMT3b* mRNA expression levels by semiquantitative RT-PCR (top) and qPCR (bottom) using β-actin as an internal control. Bar, SD.\
(B) CCD841 and HT29 cells were treated with recombinant IL-10 (100 ng/mL) for 24 hr and analyzed by western blotting analysis of DNMT1, DNMT3b (left), and IRF8 (right) protein levels.\
(C) WT (n = 4) and IL-10 KO (n = 5) mice were treated with the DSS-water cycle, as described in [STAR Methods](#S11){ref-type="sec"} for 28 days. Colon tissues were collected and analyzed by western blotting for DNMT1 and DNMT3b protein levels.\
(D) WT (n = 3) and IL-10 KO (n = 3) mice were treated with the 2% DSS-water cycle, as described in [STAR Methods](#S11){ref-type="sec"}. Colon tissues were collected at day 28 and analyzed by qPCR for the IRF8 mRNA level with β-actin as an internal control. Bar, SD.\
(E) The pGL3 vector containing the human IRF8 promoter was treated with methylase *in vitro* and transfected to CCD841 cells overnight. Cells were lysated and analyzed for luciferase activity, as described in [STAR Methods](#S11){ref-type="sec"}.](nihms-1517191-f0007){#F6}

![IL-10 Induces the Activation of STAT3 that Binds to the dnmt1 and dnmt3b Promoters in Colon Epithelial and Carcinoma Cells\
(A) WT C57BL/6 mice were treated with the 2% DSS-water cycle, as described in [STAR Methods](#S11){ref-type="sec"}. Colon tissues were collected from mice at the indicated time points and analyzed by western blotting for STAT1 and STAT3 protein levels. β-Actin was used as a normalization control.\
(B) CCD841 and HT29 cells were treated with recombinant IL-10 (100 ng/mL) for 2 hr and analyzed for the indicated proteins by western blotting.\
(C) Top: structure of the *Dnmt1* promoter region. The number below the bar indicates nucleotide locations relative to the *Dnmt1* transcription initiation site. The ChIP PCR primer regions are indicated under the bar. Bottom: CCD841 and HT29 cells were stimulated with recombinant IL-10 protein (100 ng/mL) for 16 hr, then analyzed by ChIP using immunoglobulin G (IgG) control antibody and pSTAT3-specific antibody, respectively, followed by qPCR analysis with *Dnmt1* promoter DNA-specific PCR primers, as shown at top. Input DNA was used as a normalization control. The input of each ChIP primer set was arbitrarily set at 1, and the pSTAT3 was normalized to the input DNA level. Column, mean; bar, SD.\
(D) Top: structure of the *Dnmt3b* promoter region. The number below the bar indicates nucleotide locations relative to the *Dnmt3b* transcription initiation site. The ChIP PCR primer regions are indicated under the bar. Bottom: CCD841 and HT29 cells were stimulated with recombinant IL-10 protein (100 ng/mL) for 16 hr, then analyzed by ChIP using IgG control antibody and pSTAT3-specific antibody, respectively, followed by qPCR analysis with *Dnmt3b* promoter DNA-specific PCR primers, as shown at top. Input DNA was used as a normalization control. The input of each ChIP primer set was arbitrarily set at 1, and the pSTAT3 was normalized to the input DNA level. Column, mean; bar, SD.\
(E and F) The human *DNMT1* (E) and *DNMT3b* (F) promoter DNA fragments were amplified by PCR from the two indicated regions (top: P1 and P2 for *DNMT1*, and P3 and P4 for *DNMT3b*) and cloned to the pGL3 vector. pGL3 vectors containing the P1, P2, P3, or P4 DNA fragments were transiently transfected to CCD841 and HT29 cells, respectively, overnight. Cells were either untreated (control) or treated with IL-10 (100 ng/mL) for 4 hr. Cells were lysated and analyzed for luciferase activity. Bar, SD.](nihms-1517191-f0008){#F7}
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  REAGENT or RESOURCE                                                SOURCE                                                          IDENTIFIER
  ------------------------------------------------------------------ --------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                         

  Rabbit monoclonal anti-Irf8                                        Cell Signaling Technology                                       Cat\# 5628; RRID: AB_10828231

  Mouse monoclonal anti-Stat1 (pY701)                                BD Biosciences                                                  Cat\# 612133; RRID: AB_399504

  Mouse monoclonal anti-Stat1                                        BD Biosciences                                                  Cat\# 610186; RRID: AB_397585

  Mouse monoclonal anti-Stat3 (pY705)                                BD Biosciences                                                  Cat\# 612357; RRID: AB_399646

  Mouse monoclonal anti-Stat3                                        BD Biosciences                                                  Cat\# 610190; RRID: AB_397589

  Mouse monoclonal anti-Dnmt1\[60B1220.1\]-ChIP Grade                Abcam                                                           Cat\# ab13537; RRID: AB_300438

  Mouse monoclonal anti-Dnmt3b\[52A1018\]-ChIP Grade                 Abcam                                                           Cat\# ab13604; RRID: AB_300494

  Mouse monoclonal anti- beta-Actin \[Clone AC-74\]                  Sigma-Aldrich                                                   Cat\# A2228; RRID: AB_476697

  Rat monoclonal FITC anti-mouse CD8a\[Clone 53--6.7\]               BioLegend                                                       Cat\# 100706; RRID: AB_312745

  Rat monoclonal PE anti-mouse CD4\[Clone RM4--5\]                   BioLegend                                                       Cat\# 100512; RRID: AB_312715

  Rat monoclonal FITC anti-mouse/human CD11b\[Clone\                 BioLegend                                                       Cat\# 101206; RRID: AB_312789
  M1/70\]                                                                                                                            

  Rat monoclonal PE anti-mouse Ly-6G/Ly-6C\                          BioLegend                                                       Cat\# 108408; RRID: AB_313373
  (Gr-1)\[Clone RB6--8C5\]                                                                                                           

  Rat monoclonal APC anti-mouse IL10\[Clone JES5--16E3\]             BioLegend                                                       Cat\# 505009; RRID: AB_315363

  Rabbit polyclonal anti-ki67                                        Novus                                                           Cat\# NB500--170; RRID: AB_10001977

  Horse Anti-mouse IgG, HRP-linked                                   Cell Signaling Technology                                       Cat\# 7076; RRID: AB_330924

  Goat Anti-rabbit IgG, HRP-linked                                   Cell Signaling Technology                                       Cat\# 7074; RRID: AB_2099233

  InVivo monoclonal anti-mouse/human CD11b\                          BioxCell                                                        Cat\# BE0007; RRID: AB_1107582
  \[clone M1/70\]                                                                                                                    

  Rabbit monoclonal anti-Phospho-Stat3 (Ser727)\                     Cell Signaling Technology                                       Cat\# 34911, RRID: AB_2737598
  (D4X3C)                                                                                                                            

  normal rabbit IgG-AC                                               Santa Cruz Biotechnology                                        Cat\# sc-2345; RRID: AB_737183

  Chemicals, Peptides, and Recombinant Proteins                                                                                      

  Dextran sulfate sodium (colitis grade)                             MP Biomedicals                                                  0216011050

  Azoxymethane                                                       Sigma-Aldrich                                                   A5486

  Recombinant Human IL-10 (carrier-free)                             BioLegend                                                       571002

  Recombinant Human IL-6 (carrier-free)                              BioLegend                                                       570802

  Recombinant Human IL-22 (carrier-free)                             BioLegend                                                       571302

  Recombinant Human IFN-gamma                                        R&D Systems                                                     285-IF-CF

  Beetle Luciferin, Potassium Salt                                   Promega                                                         E1601

  TRIzol Reagent                                                     Invitrogen                                                      15596018

  Hydrogen peroxide solution                                         Sigma-Aldrich                                                   216763

  VectaMount Permanent Mounting Medium                               Vector Laboratories                                             H-5000

  Hematoxylin Solution, Harris Modified                              Sigma-Aldrich                                                   HHS16

  VECTOR Methyl Green                                                Vector Laboratories                                             H-3402

  Lipofectamine 2000 Transfection Reagent                            Invitrogen                                                      11668019

  Opti-MEM Reduced Serum Medium, GlutaMAX\                           Invitrogen                                                      51985034
  Supplement                                                                                                                         

  HyClone Fetal Bovine Serum                                         ThermoFisher                                                    SH3039603

  issue-Tek O.C.T. Compound                                          Sakura                                                          4583

  Isopropanol, Molecular Biology Grade                               ThermoFisher                                                    BP2618500

  1-Butanol,anhydrous, 99.8%                                         Sigma-Aldrich                                                   281549

  Xylenes, histological grade                                        Sigma-Aldrich                                                   534056

  Chloroform                                                         Sigma-Aldrich                                                   C2432

  Blotting-Grade Blocker                                             Bio-Rad                                                         1706404

  Antigen Unmasking Solution, Citrate Based                          Vector Laboratories                                             H-3300

  ImmPACT DAB Peroxidase (HRP) Substrate                             Vector Laboratories                                             SK-4105

  S.O.C. Medium                                                      Invitrogen                                                      15544034

  Paraformaldehyde, 96%                                              ACROS Organics                                                  416785000

  Sucrose, 99+%                                                      Sigma-Aldrich                                                   S0389

  Formalin, 10% (Phosphate Buffer).                                  ThermoFisher                                                    SF100--4

  Universal-Agarose, peqGOLD                                         Peqlab                                                          351020

  3M Sodium Acetate, pH 5.2 ± 0.1                                    Corning                                                         46--033-CI

  EDTA (0.5 M), pH 8.0                                               Invitrogen                                                      15575038

  Formaldehyde                                                       ThermoFisher                                                    BP531

  Protein A Agarose/Salmon Sperm DNA                                 Millipore                                                       16--157

  BioMag^®^ Goat anti-Rat IgG                                        PolySciences                                                    84330

  Phenol:Chloroform:Isoamyl Alcohol                                  Sigma-Aldrich                                                   P2069

  Corning^®^ Trypsin EDTA 1X                                         Corning                                                         25--052-CI

  VECTASHIELD Antifade Mounting Medium with DAPI                     Vector Laboratories                                             H-1200

  DNase I, RNase-free                                                ThermoFisher                                                    EN0521

  Collagenase from Clostridium histolyticum                          Sigma-Aldrich                                                   C0130

  Hyaluronidase from bovine testes                                   Sigma-Aldrich                                                   H3506

  Platinum II Taq Hot-Start DNA Polymerase                           Invitrogen                                                      14966001

  CpG Methyltransferase (M.SssI)                                     New England Biolabs                                             M0226S

  M-MLV Reverse Transcriptase                                        Promega                                                         M170A

  Taq DNA Polymerase                                                 GenScript                                                       E00007

  FastDigest KpnI                                                    Fermentas                                                       FD0524

  FastDigest HindIII                                                 Fermentas                                                       FD0505

  FastDigest XhoI                                                    Fermentas                                                       FD0694

  X-Gal                                                              Sigma-Aldrich                                                   3117073001

  Corning 10% SDS                                                    Corning                                                         MT-46040-CI

  Yeast tRNA                                                         ThermoFisher                                                    AM7119

  Corning^®^ 500 mL RPMI 1640                                        Corning                                                         10--040-CV

  HEPES Buffer                                                       Corning                                                         MT-25060-CI

  Corning^®^ 100 mL Penicillin-Streptomycin Solution, 100x           Corning                                                         30--002-CI

  Sodium Pyruvate (100 mM)                                           GIBCO                                                           11360070

  MEM Non-Essential Amino Acids Solution (100X)                      HyClone                                                         SH3023801

  Critical Commercial Assays                                                                                                         

  ImmPRESS HRP Universal Antibody (Anti-Mouse\                       Vector Laboratories                                             MP-7500
  IgG/Anti-Rabbit IgG)                                                                                                               

  Mini-PROTEAN^®^ TGX Gels                                           Bio-Rad                                                         4561096

  Power SYBR Green PCR Master Mix                                    ThermoFisher                                                    4367659

  Chromatin Immunoprecipitation (ChIP) Assay Kit                     Millipore                                                       17295

  TA Cloning Kit, with pCR2.1 Vector and One Shot\                   Invitrogen                                                      K204001
  TOP10 Chemically Competent E. coli                                                                                                 

  ApopTag^®^ Plus Peroxidase In Situ Apoptosis Kit                   Millipore                                                       S7101

  CpGenome Universal DNA Modification Kit                            Millipore                                                       S7820

  QIAEX II Gel Extraction Kit                                        QIAGEN                                                          20021

  Fixation/Permeabilization Solution Kit with BD GolgiPlug           BD Biosciences                                                  555028

  Zyppy Plasmid Miniprep Kit                                         Zymo Research                                                   D4019

  Quick-DNA Miniprep Plus Kit                                        Zymo Research                                                   D4069

  Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate   PerkinElmer                                                     NEL105001EA

  Experimental Models: Cell Lines                                                                                                    

  Cell Line: CCD 841 CoN (ATCC CRL-1790)                             American Type Culture Collection                                [www.atcc.org/Products/All/CRL-1790.aspx](www.atcc.org/Products/All/CRL-1790.aspx)

  Cell Line: HT-29 (ATCC HTB-38)                                     American Type Culture Collection                                [atcc.org/Products/All/HTB-38.aspx](http://atcc.org/Products/All/HTB-38.aspx)

  Cell Line: HCT 116 (ATCC CCL-247)                                  American Type Culture Collection                                [www.atcc.org/products/all/CCL-247.aspx](http://www.atcc.org/products/all/CCL-247.aspx)

  Cell Line: RAW 264.7 (ATCC TIB-71)                                 American Type Culture Collection                                [www.atcc.org/Products/All/TIB-71.aspx](http://www.atcc.org/Products/All/TIB-71.aspx)

  Cell Line: HCT116DNMT1−/−                                          Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD)   [@R32]

  Cell Line: HCT116DNMT3b−/−                                         Dr. Bert Vogelstein (Johns Hopkins\                             [@R32]
                                                                     University, Baltimore, MD)                                      

  Cell Line: HCT116DNMT1−/−DNMT3b−/− (DKO)                           Dr. Bert Vogelstein (Johns Hopkins\                             [@R32]
                                                                     University, Baltimore, MD)                                      

  Mouse: B6(Cg)-Irf8^tm1.1Hm^/J                                      Jackson Laboratory                                              [www.jax.org/strain/014175](http://www.jax.org/strain/014175)

  Mouse: B6.Cg-Tg(Vil1-cre)1000Gum/J                                 Jackson Laboratory                                              [www.jax.org/strain/021504](http://www.jax.org/strain/021504)

  Mouse: B6.129P2-Il10^tm1Cgn^/J                                     Jackson Laboratory                                              [www.jax.org/strain/002251](http://www.jax.org/strain/002251)

  Mouse: B6(Cg)-Irf8^tm2.1Hm^/J                                      Jackson Laboratory                                              [www.jax.org/strain/027084](http://www.jax.org/strain/027084)

  Mouse: Irf8KO Mice                                                 Dr. Keiko Ozato -- (NIH, Bethesda, MD)                          [@R13]

  Mouse: JAX C57BL/6J Mice                                           Charles River                                                   [www.jax.org/strain/000664](http://www.jax.org/strain/000664)

  All Primers, see Table S1                                          This paper                                                      N/A

  Recombinant DNA                                                                                                                    

  pGL3 Luciferase Reporter Vector (Basic)                            Promega                                                         E1751

  MethHC                                                             [@R14]                                                          [academic.oup.com/nar/article/43/D1/D856/2438401](http://academic.oup.com/nar/article/43/D1/D856/2438401)

  UCSC Xena Browser                                                  University of California Santa Cruz                             [xenabrowser.net/heatmap](http://xenabrowser.net/heatmap)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Highlights

-   Chronic inflammation increases colonic myeloid-derived suppressor cells (MDSCs)

-   The majority of IL-10^+^ cells are MDSCs in the inflamed colon

-   IL-10 activates STAT3 to upregulate DNMT3b to methylate the *Irf8* promoter

-   IRF8 is a suppressor of inflammation-induced colon cancer
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